Two global haemostatic assays as additional tools to monitor treatment in cases of haemophilia A

Thromb Haemost. 2012 Jul;108(1):21-31. doi: 10.1160/TH11-11-0811. Epub 2012 Apr 26.

Abstract

Haemophilia A patients with similar levels of factor VIII (FVIII) may have different bleeding phenotypes and responses to treatment with FVIII concentrate. Therefore, a test which determines overall haemostasis may be appropriate for treatment monitoring in some patients. We studied two global haemostatic methods:endogenous thrombin potential (ETP) and overall haemostatic potential(OHP) before and after injection of FVIII concentrate in patients with haemophilia A treated prophylactically and on-demand. A significant correlation between FVIII and both ETP and OHP was observed, while ETP and OHP differed between patients with severe and mild clinical phenotypes. Both ETP and OHP differed significantly between severe, moderate and mild haemophilia A and controls. ETP and OHP increased after intravenous injection of FVIII concentrate in both groups of patients, but in spite of higher pre-treatment values of both ETP and OHP in patients treated prophylactically, and much higher post-treatment FVIII levels in comparison with the values in patients treated on-demand, no difference after treatment was observed for either ETP or OHP. ETP and OHP may be additional alternatives for monitoring (and even for individual tailoring) treatment in patients with haemophilia A.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Blood Coagulation Tests
  • Disease Progression
  • Drug Monitoring / methods*
  • Factor VIII / administration & dosage*
  • Factor VIII / adverse effects
  • Female
  • Hemophilia A / blood
  • Hemophilia A / drug therapy*
  • Hemostasis / drug effects*
  • Humans
  • Male
  • Middle Aged
  • Thrombin / metabolism*
  • Treatment Outcome
  • Young Adult

Substances

  • F8 protein, human
  • Factor VIII
  • Thrombin